Redeye provides an update on Xspray following its Q2 report. The company faces two near-term material events: the NDA submission of its nilotinib candidate, XS003, and the PDUFA date for its lead candidate, Dasynoc, in October, offering opportunities for near-term share price-supportive newsflow.
LÄS MER
